LOW RATE OF EXTENSIVE FIBROSIS IN YOUNG HCV PATIENTS: RE-THINKING SIMPLIFIED TREATMENT ALGORITHMS

被引：0
|
作者：
Ramji, Alnoor [1 ,2 ]
Tam, Edward V. [3 ]
MacIsaac, Julia [4 ]
Widmer, Nadia [1 ]
Wallach, Jean-Philippe [1 ]
Lewendon, Shayla [5 ]
Farivar, Jeanette Feizi [6 ]
Ko, Hin Hin [4 ]
机构：
[1] Univ British Columbia, Med, Vancouver, BC, Canada
[2] Univ British Columbia, Div Gastroenterol, Dept Med, Vancouver, BC, Canada
[3] Pacific Gastroenterol Associates, Vancouver, BC, Canada
[4] Univ British Columbia, Vancouver, BC, Canada
[5] Fraser Hlth, Surrey, BC, Canada
[6] Gastrointestinal Res Inst, Vancouver, BC, Canada
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1293
引用
收藏
页码：S384 / S385
页数：2
相关论文
共 14 条
  • [1] Challenging Perceptions: Re-Thinking Treatment of Hcv in People Who Use Drugs. Changing Perspectives of the Liver Specialist
    Rehak, V.
    [J]. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2018, 20 : 56 - 56
  • [2] Challenging Perceptions: Re-Thinking Treatment of Hcv in People Who Use Drugs. Changing Perspectives of the Liver Specialist
    Roncero, C.
    [J]. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2018, 20 : 57 - 57
  • [3] Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients
    Rullier, A
    Trimoulet, P
    Neau, D
    Bernard, PH
    [J]. HUMAN PATHOLOGY, 2004, 35 (09) : 1088 - 1094
  • [4] High rate of misclassification of fibrosis stage using transient elastography thresholds to prioritize HCV patients for antiviral treatment
    Calvaruso, V.
    Bronte, F.
    Magro, B.
    Conte, E.
    Petta, S.
    Cabibi, D.
    Craxi, A.
    Camma, C.
    Di Marco, V.
    [J]. DIGESTIVE AND LIVER DISEASE, 2017, 49 (01) : E65 - E66
  • [5] Treatment of acute cellular rejection episodes does not influence fibrosis progression rate in patients with recurrence HCV after liver transplantation
    Manousou, Pinelopi
    Tsochatzis, Emmanuel
    Parisi, Ioanna
    Saffioti, Francesca
    Mansell, Alexandra
    Aspite, Silvia
    Patch, David W.
    O'Beirne, James
    Thorburn, Douglas
    Tu Vinh Luong
    Dhillon, Amar P.
    Pinzani, Massimo
    Burroughs, Andrew K.
    [J]. HEPATOLOGY, 2014, 60 : 452A - 452A
  • [6] Low rate of hepatitis C virus re-infection following sustained virological response among injection drug users having received treatment for HCV infection
    Grebely, J.
    Ngai, T.
    Knight, E.
    Raffa, J. D.
    Genoway, K. A.
    Showler, G.
    Duncan, F.
    Krajden, M.
    Dore, G.
    Conway, B.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A338 - A338
  • [7] Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis
    Figorilli, Francesco
    Onali, Simona
    Catone, Stefania
    Argentini, Claudio
    Casu, Stefania
    Balestrieri, Cinzia
    Conti, Maria
    Serra, Giancarlo
    Casale, Michele
    Pasetto, Maria Cristina
    Matta, Laura
    Barca, Lucia
    Scioscia, Rosetta
    Canini, Irene
    Quaranta, Maria Giovanna
    Genovese, Domenico
    Vella, Stefano
    Chessa, Luchino
    [J]. HEPATOLOGY, 2015, 62 : 778A - 779A
  • [8] LOW ANTIVIRAL TREATMENT RATE FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)-A REAL-WORLD NATIONWIDE U. S. STUDY
    Kam, Leslie Yeeman
    Yeo, Yee Hui
    Ji, Fanpu
    Henry, Linda
    Cheung, Ramsey
    Nguyen, Mindie H.
    [J]. HEPATOLOGY, 2023, 78 : S62 - S62
  • [9] IL28B POLYMORPHISMS LINKED TO POOR RESPONSE TO TREATMENT ARE ASSOCIATED WITH LOW NECROINFLAMMATORY ACTIVITY AND SLOW FIBROSIS PROGRESSION IN HCV GENOTYPE NON-1-INFECTED PATIENTS
    Bochud, P-Y
    Bibert, S.
    Kutalik, Z.
    Goossens, N.
    Muellhaupt, B.
    Gerlach, T.
    Heim, M.
    Moradpour, D.
    Cerny, A.
    Malinverni, R.
    Dufour, J-F
    Negro, F.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S539 - S539
  • [10] ALISPORIVIR - A HOST-TARGETING ANTIVIRAL, PROVIDES LOW VIRAL BREAKTHROUGH RATE AND HIGH BARRIER TO RESISTANCE IN HCV GENOTYPE 1 TREATMENT-NAiVE PATIENTS IN THE PHASE IIB ESSENTIAL STUDY
    Li, Bin
    Snoeck, Joke
    Tang, Yanhua
    Jones, Christopher T.
    Tiongyip, Choilai
    Bao, Weibin
    Yu, Jing
    Vandamme, Anne-Mieke
    Vuagniaux, Gregoire
    Crabbe, Raf
    Avila, Claudio
    Naoumov, Nikolai V.
    Lin, Kai
    [J]. HEPATOLOGY, 2011, 54 : 997A - 998A
12